What is the XTRAC® excimer laser treatment?
It is a medical technology used to treat dermatologic conditions like psoriasis, vitiligo, and atopic dermatitis.
Yanuki
ARTICLE DETAIL
STRATA Skin Sciences Targets Early CMS Reimbursement for Expanded XTRAC Laser Use | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries | STRATA Skin Sciences Targets Early CMS Reimbursement for Expanded XTRAC Laser Use | Femtech Market Growth to $26 Billion by 2033: Key Insights and Opportunities | Preparing for Daylight Saving Time 2026: What You Need to Know | Oscar-Nominated Directors Highlight Workers at a Women's Health Clinic in 'The Devil Is Busy' | Trump Spotted with Rash on Neck: Possible Causes and Theories | Olympic Village Condom Shortage: A Hot Topic at the 2026 Winter Games | Talcum Powder and Cancer: Unveiling the Connection | Drug-Resistant Typhoid Fever: An Ancient Killer Returns | RFK Jr.'s CDC Panel to Discuss Covid Vaccine Injuries
Health / Dermatology
STRATA Skin Sciences Targets Early CMS Reimbursement for Expanded XTRAC Laser Use
STRATA Skin Sciences (SSKN) is actively pursuing early reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its XTRAC® excimer laser treatment. This move aims to accelerate patient access to this therapy for a broader r...
Key Insights
- STRATA is seeking temporary CMS codes to potentially allow for expanded reimbursement as early as 2026, ahead of the initially planned 2027 timeline.
- The American Medical Association has approved updates to CPT codes 96920–96922, expanding reimbursement eligibility for XTRAC Excimer Laser treatments to include all inflammatory and autoimmune skin conditions.
- Recent studies support the use of XTRAC laser therapy combined with Janus kinase (JAK) inhibitors for treating vitiligo.
- STRATA is progressing in its lawsuit against LaserOptek, with the court adding LaserOptek Korea as a defendant, alleging false advertising practices.
In-Depth Analysis
STRATA Skin Sciences is working to expedite the availability of its XTRAC laser treatment for various skin conditions. The company is seeking temporary CMS codes to accelerate reimbursement eligibility, potentially tripling the addressable patient population. This initiative is backed by clinical evidence supporting the efficacy of XTRAC laser therapy, particularly in combination with JAK inhibitors for vitiligo treatment.
Two recent studies published in the *International Journal of Dermatology* and *Human Vaccines and Immunotherapeutics* highlight the benefits of combining excimer laser therapy with JAK inhibitors. The studies demonstrated significant re-pigmentation and pigment stability in patients with vitiligo. In addition to these clinical advancements, STRATA is actively pursuing legal action against LaserOptek for alleged false advertising practices related to Pallas lasers.
STRATA’s CEO, Dr. Dolev Rafaeli, emphasizes that expanding access to XTRAC is about providing effective, non-drug therapy to millions of patients with chronic inflammatory skin conditions. The company’s efforts aim to create economic incentives for providers to offer this care, positioning XTRAC as a leading drug-free option in dermatology.
FAQ
What is STRATA Skin Sciences trying to achieve with CMS?
They are seeking temporary codes for expanded reimbursement of XTRAC® treatments, aiming to make these treatments reimbursable by 2026.
What skin conditions could be treated with XTRAC if the reimbursement is expanded?
Inflammatory and autoimmune skin conditions, such as vitiligo, atopic dermatitis, and alopecia areata, in addition to psoriasis.
Takeaways
- STRATA Skin Sciences is striving to make its XTRAC laser treatment more accessible for various skin conditions.
- New research supports the effectiveness of combining XTRAC laser therapy with JAK inhibitors, particularly for vitiligo.
- The company is also involved in legal action to protect its market position.
Discussion
Do you think this expanded access to XTRAC laser treatment will significantly impact the dermatology market? Let us know!
Share this article with others who need to stay ahead of this trend!
Sources
STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients
STRATA Skin Sciences Targets Early CMS Reimbursement for Expanded XTRAC Laser Use, Cites New Vitiligo Study and Legal Victory
Strata Skin Sciences Secures Temporary Reimbursement Codes
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.